Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17642357 | 1.00 | CA2 (0.48) | CA2CA9CA12KMT2APOLB | |
| SCHEMBL17637928 | 0.86 | KDM4E (0.46) | CA2CA9KMT2APOLBCA1 | |
| SCHEMBL17628493 | 0.86 | KDM4E (0.46) | CA2CA9KMT2APOLBCA1 | |
| SCHEMBL19255899 | 0.78 | NPC1 (0.58) | KMT2APOLBGLAMAPTALDH1A1 | |
| SCHEMBL17637926 | 0.77 | CYP1A2 (0.55) | KMT2AGLAMAPTALDH1A1RECQL | |
| SCHEMBL11270822 | 0.74 | KMT2A (0.60) | CA2CA9CA12KMT2APOLB | |
| SCHEMBL2070966 | 0.74 | KMT2A (0.60) | CA2CA9CA12KMT2APOLB | |
| SCHEMBL24106342 | 0.72 | MAPT (0.53) | CA2CA9CA12KMT2APOLB | |
| SCHEMBL7922108 | 0.72 | KMT2A (0.62) | CA2CA9CA12KMT2APOLB | |
| SCHEMBL3651298 | 0.69 | HSD11B1 (0.66) | KMT2APOLBHSD11B1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004065-B1 | METHOD FOR PRODUCING PYRIDAZINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-10-18 | — | — | EP | disclosed |
| US-9732042-B2 | Method for producing pyridazine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160090363-A1 | METHOD FOR PRODUCING PYRIDAZINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090363-A1 | METHOD FOR PRODUCING PYRIDAZINE COMPOUND | PLP2, PNPO, CBR3 | CA2 2397/4885CA9 2194/4885CA12 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.